Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
8348(c) 8343(c) 8404(c) 8383(c) 8384(c) Last
1 475 572 1 254 639 1 563 171 1 617 289 3 563 894 Volume
+0.10% -0.06% +0.73% -0.25% +0.01% Change
More quotes
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,5x
Yield 2021 2,46%
Sales 2022 35 407 M - -
Net income 2022 6 810 M - -
Net Debt 2022 8 377 M - -
P/E ratio 2022 24,5x
Yield 2022 2,55%
Capitalization 152 B 152 B -
EV / Sales 2021 5,25x
EV / Sales 2022 4,53x
Nbr of Employees 76 100
Free-Float 95,7%
More Financials
Company
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with... 
Sector
Pharmaceuticals
Calendar
06/18Presentation
More about the company
Ratings of AstraZeneca PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ASTRAZENECA PLC
05:07pOntarians cancelling AZ doses after new guidance, province still offering dos..
AQ
05:04pHealth Care Down Amid Defensive Bias -- Health Care Roundup
DJ
04:01pU.S.-CANADA BORDER COULD REOPEN TO F : Legault
AQ
12:12pEurostoxx 50 : European shares deepen losses after hawkish Fed comments
RE
11:25aTHE LATEST : Brazil to hit 500K deaths, 2nd highest globally
AQ
11:18aASTRAZENECA  : Ordered by Brussels Court to Deliver 80.2 Million COVID-19 Jabs t..
MT
10:40aASTRAZENECA  : claims victory over EU in vaccine deliveries case
AQ
10:30aASTRAZENECA  : EU both claim a win in vaccine delivery tussle
AQ
09:50aASTRAZENECA  : Welcomes Belgian Court Ruling on COVID-19 Vaccine Supply to EU
MT
09:31aASTRAZENECA  : Court orders AstraZeneca to deliver 50 million doses to EU by Sep..
AQ
09:06aASTRAZENECA  : EU loses bid for speedier AstraZeneca vaccine deliveries
RE
08:24aASTRAZENECA  : Vaccine-maker AstraZeneca claims victory in court tussle with EU ..
AQ
08:11aASTRAZENECA  : welcomes Court ruling on supply of its COVID-19 vaccine to Europe
PU
08:01aAstraZeneca Ordered to Deliver Vaccine Doses to EU Amid Lawsuit -- Update
DJ
07:22aUNIVERSITY OF CAMBRIDGE : Apollo Therapeutics launches with GBP100m investment; ..
AQ
More news
News in other languages on ASTRAZENECA PLC
12:46pAcciones europeas profundizan sus pérdidas tras los comentarios de la Fed
11:00aGericht gibt EU-Kommission im Streit mit Impfstoffhersteller Astrazeneca Rech..
10:04aCORONAVIRUS : AstraZeneca annonce le rejet d'un recours déposé par Bruxelles sur..
09:50aVACCINS ASTRAZENECA : l'UE obtient en justice moins de doses que réclamé
09:43aZuversicht bei Reisen und Impfen - Sorge vor Delta-Variante
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 133,03 $
Last Close Price 115,73 $
Spread / Highest target 47,7%
Spread / Average Target 14,9%
Spread / Lowest Target -16,8%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.47%153 347
JOHNSON & JOHNSON4.98%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939